Skip to content
Adventris Pharmaceuticals logo

Adventris Pharmaceuticals

Adventris Pharmaceuticals is a YC Winter 2023 (W23) company. Based in Baltimore, MD, USA. Team of 7.

  • Biotech
  • Healthcare
  • Therapeutics
  • Drug discovery
  • Oncology

About Adventris Pharmaceuticals

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Adventris Pharmaceuticals develops off-the-shelf cancer vaccines that target poorly immunogenic oncogenes. Its lead program targets KRAS, the most commonly mutated cancer-driving gene, replacing the need for personalized or patient-specific vaccine manufacturing. The long-term goal is a pan-cancer vaccine administered annually to healthy adults, shifting cancer management from treatment to prevention.

From the Y Combinator listing

How Adventris Pharmaceuticals describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Adventris makes cancer vaccines

Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
Baltimore, MD, USA
Team size
7
Status
Active
Stage
Early

Founders (3)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works